Skip to main content
. 2011 Aug 6;32(9):2759–2767. doi: 10.1007/s00296-011-2033-5

Table 4.

Parameters with significant partial correlation with FFbH changes at month 12 in the regression analysis set

Regression model FFbH, N  = 2,625 Model values
Constant Total R² P-value
36.647 0.205 <0.001
Variable Value Beta-weight Partial r 2 P-value
Positive predictors for increase in functional capacity
 Employment 1 = yes, 0 = no 3.078 0.023 <0.001
 Gender 1 = male, 0 = female 3.160 0.005 <0.001
 COX-2 inhibitors 1 = yes, 0 = no 2.892 0.005 <0.001
 ESR Continuous 0.047 0.004 <0.001
 Patient global assessment Number (0–10) 0.653 0.003 <0.001
Negative predictors for increase in functional capacity
 Baseline FFbHa Continuous (0–100% points) −0.317 0.126 <0.001
 Disease duration Continuous −0.171 0.017 <0.001
 Joint replacement 1 = yes, 0 = no −4.277 0.008 <0.001
 Age (years) Continuous −0.123 0.005 <0.001
 Previous biologics Number (0, 1, 2, 3, 4) −2.149 0.005 <0.001
 BMI (kg/m²) Continuous −0.258 0.005 <0.001

BMI body mass index, COX-2 cyclo-oxygenase 2, ESR erythrocyte sedimentation rate, FFbH Funktionsfragebogen Hannover functional capacity questionnaire, MTX methotrexate

aHigh FFbH values indicate high functional capacity (low impairment)